|
|
Blood, Vol. 113, Issue 11, 2442-2450, March 12, 2009
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
Blood Louis et al.
113: 2442
Supplemental materials for: Louis et al
Additional clinical information for patient P1740
Patient 1740 was initially diagnosed with NPC in 2′2002 and was started on POG 9486 (5-FU, MTX, CDDP). She only received one course of chemotherapy due to acute renal failure requiring dialysis. From 4/2002 to 6/2002, she received XRT with 5400cGy and was in remission at the end of therapy. She had a local recurrence in 12/2002 and was treated with surgical resection and 4 courses of MTX and 5-FU. From 4/3/2003 until 5/3/2005, she was in remission before developing another local recurrence. She was treated with oxaliplatin on COG-ADVL0421 with no response and then received 5 cycles of taxol, carboplatin, and gemcitabine. Two weeks after completion of her last course of chemotherapy, she had a MRI as well as a PET scan showing active disease. She was then enrolled on our CTL study; since then she had multiple PET scans (last 2′08) which showed no evidence of disease. On MRI, there is a residual mass, which has been stable for the last 2 years. A biopsy performed 9′2006 was consistent with “scar tissue” and no evidence of malignancy; in addition EBV stains (EBER and LMP1) were both negative.
Files in this Data Supplement:
|
|
